Skip to main content
. 2016 Dec 26;8(5):8315–8329. doi: 10.18632/oncotarget.14174

Table 1. Clinicopathological characteristics of the ESCC cohort.

All patients Patients with Stage I-II disease Patients without lymph node metastasis
n % n % n %
Sex
   Female 46 16.5 35 20.8 29 20
   Male 232 83.5 133 79.2 116 80
Age
   <60 116 41.7 62 36.9 51 35.2
   ≥60 162 58.3 106 63.1 94 64.8
Smoking
   No 162 58.3 110 65.5 95 65.5
   Yes 115 41.4 57 33.9 49 33.8
Differentiation
   Well 7 2.5 4 2.4 4 2.8
   Moderate 156 56.1 97 57.7 85 58.6
   Poor 115 41.4 67 39.9 56 38.6
Invasive depth
   I 89 32 82 48.8 61 42.1
   II 189 68 86 51.2 84 57.9
Vessel involvement
   No 227 81.7 157 93.5 137 94.5
   Yes 51 18.3 11 6.5 8 5.5
Nerve involvement
   No 205 73.7 137 81.5 116 80
   Yes 73 26.3 31 18.5 29 20
Lymph node metastasis
   No 145 52.2 135 80.4
   Yes 133 47.8 33 19.6
Tumor site
   Upper 13 4.7 8 4.8 7 4.8
   Middle 131 47.1 83 49.4 73 50.3
   Low 123 44.2 66 39.3 54 37.2
Clinical stage
   I-II 168 60.4 135 93.1
   III-Iva 110 39.6 10 6.9
tPD-L1 ≥1%
   No 137 49.3 88 52.4 73 50.3
   Yes 141 50.7 80 47.6 72 49.7
tPD-L1 ≥5%
   No 153 55 96 57.1 78 53.8
   Yes 125 45 72 42.9 67 46.2
tPD-L1 ≥10%
   No 180 64.7 116 69 95 65.5
   Yes 98 35.3 52 31 50 34.5
tPD-L1 ≥20%
   No 199 71.6 124 73.8 102 70.3
   Yes 79 28.4 44 26.2 43 29.7
tPD-L1 ≥30%
   No 221 79.5 134 79.8 113 77.9
   Yes 57 20.5 34 20.2 32 22.1
tPD-L1 ≥50%
   No 233 83.8 142 84.5 121 83.4
   Yes 45 16.2 26 15.5 24 16.6
sPD-L1 ≥1%
   No 162 58.3 97 57.7 88 60.7
   Yes 116 41.7 71 42.3 57 39.3
sPD-L1 ≥5%
   No 171 61.5 103 61.3 91 62.8
   Yes 107 38.5 65 38.7 54 37.2
sPD-L1 ≥10%
   No 235 84.5 142 84.5 121 83.4
   Yes 43 15.5 26 15.5 24 16.6
sPD-L1 ≥20%
   No 236 84.9 142 84.5 121 83.4
   Yes 42 15.1 26 15.5 24 16.6
sPD-L1 ≥30%
   No 249 89.6 150 89.3 128 88.3
   Yes 29 10.4 18 10.7 17 11.7
sPD-L1 ≥50%
   No 260 93.5 157 93.5 134 92.4
   Yes 18 6.5 11 6.5 11 7.6

Invasive depth I, tumor invasion confined to muscularis; Invasive depth II, tumor invasion beyond the muscularis.

tPD-L1, Tumoral PD-L1 expression; sPD-L1, Stromal PD-L1 expression.